<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591760</url>
  </required_header>
  <id_info>
    <org_study_id>GH replacement in CHF</org_study_id>
    <nct_id>NCT00591760</nct_id>
  </id_info>
  <brief_title>Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial</brief_title>
  <official_title>Correction of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the potential benefits of the correction of growth
      hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure
      due to left ventricular systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, a wide range of alterations in the GH/IGF-1 axis have been described in patients
      with chronic heart failure (CHF): reductions in GH levels, reductions in IGF-1 and a pattern
      of peripheral resistance to GH, in particular in patients with severe heart failure and
      cardiac cachexia. Unpublished experience of our group support the concept that a considerable
      amount of CHF-patients have a coexisting Growth Hormone Deficiency (GHD), defined by current
      guidelines(GH stimulation test).

      Our study hypothesis is that correction of GH deficiency in patients with chronic heart
      failure may exert a beneficial effect on their cardiac function and remodeling, performance
      status and quality-of-life.

      Since this was a preliminary study, no sample size calculation was performed; treatment
      effects from were sought in left ventricular function (as assessed by cardiac MRI),
      cardiopulmonary exercise performance, clinical status, vascular reactivity, biochemistry and
      neurohumoral markers of disease (NT-proBNP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>6 months</time_frame>
    <description>changes in peak VO2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Heart Failure</condition>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>GH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatotropin</intervention_name>
    <description>Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months</description>
    <arm_group_label>GH</arm_group_label>
    <other_name>rhGH</other_name>
    <other_name>Saizen</other_name>
    <other_name>NutropinAq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart Failure in ew York Heart Association functional class II to IV

          -  Left ventricular end diastolic diameter &gt; 60 mm

          -  Left ventricular ejection fraction &lt; 40%

          -  Growth Hormone Deficiency (defined as a peak GH response to intravenous stimulation
             with GHRH + Arginine &lt; 9 ng/dl)

          -  Age 18-80 years

          -  Clinical stability, guideline-oriented maximal pharmacological therapy

          -  Informed consent

        Exclusion Criteria:

          -  Active Myocarditis

          -  Hypertrophic Cardiomyopathy

          -  Active endocarditis

          -  Active malignancy

          -  End stage renal disease

          -  Severe liver disease (Child B-C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cittadini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University - Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Sacc√†, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>March 23, 2009</results_first_submitted>
  <results_first_submitted_qc>October 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Antonio Cittadini</name_title>
    <organization>Federico II University</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Anabolism</keyword>
  <keyword>Anabolic Deficiency</keyword>
  <keyword>Hormone replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty-three patients with CHF NYHA class II-IV and GH deficiency were enrolled from December 2004 to December 2006. These patients were consecutively selected from a cohort of 158 ambulatory patients referred to our tertiary care center and, to a minor extent, patients hospitalized for CHF.</recruitment_details>
      <pre_assignment_details>Patients recruited during hospital stay were studied after a 3-months period of optimized medical therapy and clinical stability</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GH Replacement Therapy</title>
          <description>Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Optimal CHF treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GH Replacement Therapy</title>
          <description>Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Optimal CHF treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="6"/>
                    <measurement group_id="B2" value="62" spread="8"/>
                    <measurement group_id="B3" value="62" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>echocardiography</title>
          <units>% of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="B2" value="40" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="B3" value="35" lower_limit="20" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak VO2</title>
        <description>changes in peak VO2</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GH Replacement Therapy</title>
            <description>Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Optimal CHF treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Peak VO2</title>
          <description>changes in peak VO2</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="1.0"/>
                    <measurement group_id="O2" value="12.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GH Replacement Therapy</title>
          <description>Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,00415 mg/kg a day, added to their background optimized CHF therapy</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Optimal CHF treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Antonio Cittadini</name_or_title>
      <organization>Federico II University</organization>
      <phone>0039(0)817464375</phone>
      <email>antonio.cittadini@unina.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

